Broadly Reactive IgG Responses to Heterologous H5 Prime-Boost Influenza Vaccination Are Shaped by Antigenic Relatedness to Priming Strains

The antigenic shift and draft of hemagglutinin (HA) in influenza viruses is accepted as one of the major reasons for immune evasion. The analysis of B cell immune responses to influenza infection and vaccination is complicated by the impact of exposure history and antibody cross-reactions between an...

Full description

Saved in:
Bibliographic Details
Published inmBio Vol. 12; no. 4; p. e0044921
Main Authors Wang, Jiong, Li, Dongmei, Perry, Sheldon, Hilchey, Shannon P., Wiltse, Alexander, Treanor, John J., Sangster, Mark Y., Zand, Martin S.
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 31.08.2021
Subjects
Online AccessGet full text
ISSN2150-7511
2150-7511
DOI10.1128/mBio.00449-21

Cover

Abstract The antigenic shift and draft of hemagglutinin (HA) in influenza viruses is accepted as one of the major reasons for immune evasion. The analysis of B cell immune responses to influenza infection and vaccination is complicated by the impact of exposure history and antibody cross-reactions between antigenically similar influenza strains. Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual’s H5 exposure history on antibody responses to subsequent H5 vaccination is poorly understood. To investigate this, we analyzed the IgG responses to H5 influenza A/Indonesia/5/2005 (Ind05) virus vaccination in three cohorts: (i) a doubly primed group that had received two H5 virus vaccinations, namely, against influenza A/Vietnam/203/2004 (Vie04) virus 5 years prior and A/Hong Kong/156/1997 (HK97) 11 years prior to the Ind05 vaccination; (ii) a singly primed group that had received a vaccination against Vie04 virus 5 years prior to the Ind05 vaccination; and (iii) an H5-naive group that received two doses of the Ind05 vaccine 28 days apart. Hemagglutinin (HA)-reactive IgG levels were estimated by a multiplex assay against an HA panel that included 21 H5 strains and 9 other strains representing the H1, H3, H7, and H9 subtypes. Relative HA antibody landscapes were generated to quantitatively analyze the magnitude and breadth of antibody binding after vaccination. We found that short-interval priming and boosting with the Ind05 vaccine in the naive group generated a low anti-H5 response. Both primed groups generated robust antibody responses reactive to a broad range of H5 strains after receiving a booster injection of Ind05 vaccine; IgG antibody levels persisted longer in subjects who had been doubly primed years ago. Notably, the IgG responses were strongest against the first priming H5 strain, which reflects influenza virus immune imprinting. Finally, the broad anti-H5 IgG response was stronger against strains having a small antigenic distance from the initial priming strain. IMPORTANCE The antigenic shift and draft of hemagglutinin (HA) in influenza viruses is accepted as one of the major reasons for immune evasion. The analysis of B cell immune responses to influenza infection and vaccination is complicated by the impact of exposure history and antibody cross-reactions between antigenically similar influenza strains. To assist in such analyses, the influenza “antibody landscape” method has been used to analyze and visualize the relationship of antibody-mediated immunity to antigenic distances between influenza strains. In this study, we describe a “relative antibody landscape” method that calculates the antigenic distance between the vaccine influenza strain and other H5 strains and uses this relative antigenic distance to plot the anti-H5 IgG levels postvaccination. This new method quantitatively estimates and visualizes the correlation between the humoral response to a particular influenza strain and the antigenic distance from other strains. Our findings demonstrate the effect of a subject’s H5 exposure history on H5 vaccine responses quantified by the relative antibody landscape method.
AbstractList Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual’s H5 exposure history on antibody responses to subsequent H5 vaccination is poorly understood. To investigate this, we analyzed the IgG responses to H5 influenza A/Indonesia/5/2005 (Ind05) virus vaccination in three cohorts: (i) a doubly primed group that had received two H5 virus vaccinations, namely, against influenza A/Vietnam/203/2004 (Vie04) virus 5 years prior and A/Hong Kong/156/1997 (HK97) 11 years prior to the Ind05 vaccination; (ii) a singly primed group that had received a vaccination against Vie04 virus 5 years prior to the Ind05 vaccination; and (iii) an H5-naive group that received two doses of the Ind05 vaccine 28 days apart. Hemagglutinin (HA)-reactive IgG levels were estimated by a multiplex assay against an HA panel that included 21 H5 strains and 9 other strains representing the H1, H3, H7, and H9 subtypes. Relative HA antibody landscapes were generated to quantitatively analyze the magnitude and breadth of antibody binding after vaccination. We found that short-interval priming and boosting with the Ind05 vaccine in the naive group generated a low anti-H5 response. Both primed groups generated robust antibody responses reactive to a broad range of H5 strains after receiving a booster injection of Ind05 vaccine; IgG antibody levels persisted longer in subjects who had been doubly primed years ago. Notably, the IgG responses were strongest against the first priming H5 strain, which reflects influenza virus immune imprinting. Finally, the broad anti-H5 IgG response was stronger against strains having a small antigenic distance from the initial priming strain.
Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual's H5 exposure history on antibody responses to subsequent H5 vaccination is poorly understood. To investigate this, we analyzed the IgG responses to H5 influenza A/Indonesia/5/2005 (Ind05) virus vaccination in three cohorts: (i) a doubly primed group that had received two H5 virus vaccinations, namely, against influenza A/Vietnam/203/2004 (Vie04) virus 5 years prior and A/Hong Kong/156/1997 (HK97) 11 years prior to the Ind05 vaccination; (ii) a singly primed group that had received a vaccination against Vie04 virus 5 years prior to the Ind05 vaccination; and (iii) an H5-naive group that received two doses of the Ind05 vaccine 28 days apart. Hemagglutinin (HA)-reactive IgG levels were estimated by a multiplex assay against an HA panel that included 21 H5 strains and 9 other strains representing the H1, H3, H7, and H9 subtypes. Relative HA antibody landscapes were generated to quantitatively analyze the magnitude and breadth of antibody binding after vaccination. We found that short-interval priming and boosting with the Ind05 vaccine in the naive group generated a low anti-H5 response. Both primed groups generated robust antibody responses reactive to a broad range of H5 strains after receiving a booster injection of Ind05 vaccine; IgG antibody levels persisted longer in subjects who had been doubly primed years ago. Notably, the IgG responses were strongest against the first priming H5 strain, which reflects influenza virus immune imprinting. Finally, the broad anti-H5 IgG response was stronger against strains having a small antigenic distance from the initial priming strain. The antigenic shift and draft of hemagglutinin (HA) in influenza viruses is accepted as one of the major reasons for immune evasion. The analysis of B cell immune responses to influenza infection and vaccination is complicated by the impact of exposure history and antibody cross-reactions between antigenically similar influenza strains. To assist in such analyses, the influenza "antibody landscape" method has been used to analyze and visualize the relationship of antibody-mediated immunity to antigenic distances between influenza strains. In this study, we describe a "relative antibody landscape" method that calculates the antigenic distance between the vaccine influenza strain and other H5 strains and uses this relative antigenic distance to plot the anti-H5 IgG levels postvaccination. This new method quantitatively estimates and visualizes the correlation between the humoral response to a particular influenza strain and the antigenic distance from other strains. Our findings demonstrate the effect of a subject's H5 exposure history on H5 vaccine responses quantified by the relative antibody landscape method.
Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual's H5 exposure history on antibody responses to subsequent H5 vaccination is poorly understood. To investigate this, we analyzed the IgG responses to H5 influenza A/Indonesia/5/2005 (Ind05) virus vaccination in three cohorts: (i) a doubly primed group that had received two H5 virus vaccinations, namely, against influenza A/Vietnam/203/2004 (Vie04) virus 5 years prior and A/Hong Kong/156/1997 (HK97) 11 years prior to the Ind05 vaccination; (ii) a singly primed group that had received a vaccination against Vie04 virus 5 years prior to the Ind05 vaccination; and (iii) an H5-naive group that received two doses of the Ind05 vaccine 28 days apart. Hemagglutinin (HA)-reactive IgG levels were estimated by a multiplex assay against an HA panel that included 21 H5 strains and 9 other strains representing the H1, H3, H7, and H9 subtypes. Relative HA antibody landscapes were generated to quantitatively analyze the magnitude and breadth of antibody binding after vaccination. We found that short-interval priming and boosting with the Ind05 vaccine in the naive group generated a low anti-H5 response. Both primed groups generated robust antibody responses reactive to a broad range of H5 strains after receiving a booster injection of Ind05 vaccine; IgG antibody levels persisted longer in subjects who had been doubly primed years ago. Notably, the IgG responses were strongest against the first priming H5 strain, which reflects influenza virus immune imprinting. Finally, the broad anti-H5 IgG response was stronger against strains having a small antigenic distance from the initial priming strain. IMPORTANCE The antigenic shift and draft of hemagglutinin (HA) in influenza viruses is accepted as one of the major reasons for immune evasion. The analysis of B cell immune responses to influenza infection and vaccination is complicated by the impact of exposure history and antibody cross-reactions between antigenically similar influenza strains. To assist in such analyses, the influenza "antibody landscape" method has been used to analyze and visualize the relationship of antibody-mediated immunity to antigenic distances between influenza strains. In this study, we describe a "relative antibody landscape" method that calculates the antigenic distance between the vaccine influenza strain and other H5 strains and uses this relative antigenic distance to plot the anti-H5 IgG levels postvaccination. This new method quantitatively estimates and visualizes the correlation between the humoral response to a particular influenza strain and the antigenic distance from other strains. Our findings demonstrate the effect of a subject's H5 exposure history on H5 vaccine responses quantified by the relative antibody landscape method.Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual's H5 exposure history on antibody responses to subsequent H5 vaccination is poorly understood. To investigate this, we analyzed the IgG responses to H5 influenza A/Indonesia/5/2005 (Ind05) virus vaccination in three cohorts: (i) a doubly primed group that had received two H5 virus vaccinations, namely, against influenza A/Vietnam/203/2004 (Vie04) virus 5 years prior and A/Hong Kong/156/1997 (HK97) 11 years prior to the Ind05 vaccination; (ii) a singly primed group that had received a vaccination against Vie04 virus 5 years prior to the Ind05 vaccination; and (iii) an H5-naive group that received two doses of the Ind05 vaccine 28 days apart. Hemagglutinin (HA)-reactive IgG levels were estimated by a multiplex assay against an HA panel that included 21 H5 strains and 9 other strains representing the H1, H3, H7, and H9 subtypes. Relative HA antibody landscapes were generated to quantitatively analyze the magnitude and breadth of antibody binding after vaccination. We found that short-interval priming and boosting with the Ind05 vaccine in the naive group generated a low anti-H5 response. Both primed groups generated robust antibody responses reactive to a broad range of H5 strains after receiving a booster injection of Ind05 vaccine; IgG antibody levels persisted longer in subjects who had been doubly primed years ago. Notably, the IgG responses were strongest against the first priming H5 strain, which reflects influenza virus immune imprinting. Finally, the broad anti-H5 IgG response was stronger against strains having a small antigenic distance from the initial priming strain. IMPORTANCE The antigenic shift and draft of hemagglutinin (HA) in influenza viruses is accepted as one of the major reasons for immune evasion. The analysis of B cell immune responses to influenza infection and vaccination is complicated by the impact of exposure history and antibody cross-reactions between antigenically similar influenza strains. To assist in such analyses, the influenza "antibody landscape" method has been used to analyze and visualize the relationship of antibody-mediated immunity to antigenic distances between influenza strains. In this study, we describe a "relative antibody landscape" method that calculates the antigenic distance between the vaccine influenza strain and other H5 strains and uses this relative antigenic distance to plot the anti-H5 IgG levels postvaccination. This new method quantitatively estimates and visualizes the correlation between the humoral response to a particular influenza strain and the antigenic distance from other strains. Our findings demonstrate the effect of a subject's H5 exposure history on H5 vaccine responses quantified by the relative antibody landscape method.
Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual’s H5 exposure history on antibody responses to subsequent H5 vaccination is poorly understood. To investigate this, we analyzed the IgG responses to H5 influenza A/Indonesia/5/2005 (Ind05) virus vaccination in three cohorts: (i) a doubly primed group that had received two H5 virus vaccinations, namely, against influenza A/Vietnam/203/2004 (Vie04) virus 5 years prior and A/Hong Kong/156/1997 (HK97) 11 years prior to the Ind05 vaccination; (ii) a singly primed group that had received a vaccination against Vie04 virus 5 years prior to the Ind05 vaccination; and (iii) an H5-naive group that received two doses of the Ind05 vaccine 28 days apart. Hemagglutinin (HA)-reactive IgG levels were estimated by a multiplex assay against an HA panel that included 21 H5 strains and 9 other strains representing the H1, H3, H7, and H9 subtypes. Relative HA antibody landscapes were generated to quantitatively analyze the magnitude and breadth of antibody binding after vaccination. We found that short-interval priming and boosting with the Ind05 vaccine in the naive group generated a low anti-H5 response. Both primed groups generated robust antibody responses reactive to a broad range of H5 strains after receiving a booster injection of Ind05 vaccine; IgG antibody levels persisted longer in subjects who had been doubly primed years ago. Notably, the IgG responses were strongest against the first priming H5 strain, which reflects influenza virus immune imprinting. Finally, the broad anti-H5 IgG response was stronger against strains having a small antigenic distance from the initial priming strain. IMPORTANCE The antigenic shift and draft of hemagglutinin (HA) in influenza viruses is accepted as one of the major reasons for immune evasion. The analysis of B cell immune responses to influenza infection and vaccination is complicated by the impact of exposure history and antibody cross-reactions between antigenically similar influenza strains. To assist in such analyses, the influenza “antibody landscape” method has been used to analyze and visualize the relationship of antibody-mediated immunity to antigenic distances between influenza strains. In this study, we describe a “relative antibody landscape” method that calculates the antigenic distance between the vaccine influenza strain and other H5 strains and uses this relative antigenic distance to plot the anti-H5 IgG levels postvaccination. This new method quantitatively estimates and visualizes the correlation between the humoral response to a particular influenza strain and the antigenic distance from other strains. Our findings demonstrate the effect of a subject’s H5 exposure history on H5 vaccine responses quantified by the relative antibody landscape method.
ABSTRACT Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual’s H5 exposure history on antibody responses to subsequent H5 vaccination is poorly understood. To investigate this, we analyzed the IgG responses to H5 influenza A/Indonesia/5/2005 (Ind05) virus vaccination in three cohorts: (i) a doubly primed group that had received two H5 virus vaccinations, namely, against influenza A/Vietnam/203/2004 (Vie04) virus 5 years prior and A/Hong Kong/156/1997 (HK97) 11 years prior to the Ind05 vaccination; (ii) a singly primed group that had received a vaccination against Vie04 virus 5 years prior to the Ind05 vaccination; and (iii) an H5-naive group that received two doses of the Ind05 vaccine 28 days apart. Hemagglutinin (HA)-reactive IgG levels were estimated by a multiplex assay against an HA panel that included 21 H5 strains and 9 other strains representing the H1, H3, H7, and H9 subtypes. Relative HA antibody landscapes were generated to quantitatively analyze the magnitude and breadth of antibody binding after vaccination. We found that short-interval priming and boosting with the Ind05 vaccine in the naive group generated a low anti-H5 response. Both primed groups generated robust antibody responses reactive to a broad range of H5 strains after receiving a booster injection of Ind05 vaccine; IgG antibody levels persisted longer in subjects who had been doubly primed years ago. Notably, the IgG responses were strongest against the first priming H5 strain, which reflects influenza virus immune imprinting. Finally, the broad anti-H5 IgG response was stronger against strains having a small antigenic distance from the initial priming strain. IMPORTANCE The antigenic shift and draft of hemagglutinin (HA) in influenza viruses is accepted as one of the major reasons for immune evasion. The analysis of B cell immune responses to influenza infection and vaccination is complicated by the impact of exposure history and antibody cross-reactions between antigenically similar influenza strains. To assist in such analyses, the influenza “antibody landscape” method has been used to analyze and visualize the relationship of antibody-mediated immunity to antigenic distances between influenza strains. In this study, we describe a “relative antibody landscape” method that calculates the antigenic distance between the vaccine influenza strain and other H5 strains and uses this relative antigenic distance to plot the anti-H5 IgG levels postvaccination. This new method quantitatively estimates and visualizes the correlation between the humoral response to a particular influenza strain and the antigenic distance from other strains. Our findings demonstrate the effect of a subject’s H5 exposure history on H5 vaccine responses quantified by the relative antibody landscape method.
The antigenic shift and draft of hemagglutinin (HA) in influenza viruses is accepted as one of the major reasons for immune evasion. The analysis of B cell immune responses to influenza infection and vaccination is complicated by the impact of exposure history and antibody cross-reactions between antigenically similar influenza strains. Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual’s H5 exposure history on antibody responses to subsequent H5 vaccination is poorly understood. To investigate this, we analyzed the IgG responses to H5 influenza A/Indonesia/5/2005 (Ind05) virus vaccination in three cohorts: (i) a doubly primed group that had received two H5 virus vaccinations, namely, against influenza A/Vietnam/203/2004 (Vie04) virus 5 years prior and A/Hong Kong/156/1997 (HK97) 11 years prior to the Ind05 vaccination; (ii) a singly primed group that had received a vaccination against Vie04 virus 5 years prior to the Ind05 vaccination; and (iii) an H5-naive group that received two doses of the Ind05 vaccine 28 days apart. Hemagglutinin (HA)-reactive IgG levels were estimated by a multiplex assay against an HA panel that included 21 H5 strains and 9 other strains representing the H1, H3, H7, and H9 subtypes. Relative HA antibody landscapes were generated to quantitatively analyze the magnitude and breadth of antibody binding after vaccination. We found that short-interval priming and boosting with the Ind05 vaccine in the naive group generated a low anti-H5 response. Both primed groups generated robust antibody responses reactive to a broad range of H5 strains after receiving a booster injection of Ind05 vaccine; IgG antibody levels persisted longer in subjects who had been doubly primed years ago. Notably, the IgG responses were strongest against the first priming H5 strain, which reflects influenza virus immune imprinting. Finally, the broad anti-H5 IgG response was stronger against strains having a small antigenic distance from the initial priming strain. IMPORTANCE The antigenic shift and draft of hemagglutinin (HA) in influenza viruses is accepted as one of the major reasons for immune evasion. The analysis of B cell immune responses to influenza infection and vaccination is complicated by the impact of exposure history and antibody cross-reactions between antigenically similar influenza strains. To assist in such analyses, the influenza “antibody landscape” method has been used to analyze and visualize the relationship of antibody-mediated immunity to antigenic distances between influenza strains. In this study, we describe a “relative antibody landscape” method that calculates the antigenic distance between the vaccine influenza strain and other H5 strains and uses this relative antigenic distance to plot the anti-H5 IgG levels postvaccination. This new method quantitatively estimates and visualizes the correlation between the humoral response to a particular influenza strain and the antigenic distance from other strains. Our findings demonstrate the effect of a subject’s H5 exposure history on H5 vaccine responses quantified by the relative antibody landscape method.
Author Li, Dongmei
Wiltse, Alexander
Sangster, Mark Y.
Treanor, John J.
Zand, Martin S.
Wang, Jiong
Perry, Sheldon
Hilchey, Shannon P.
Author_xml – sequence: 1
  givenname: Jiong
  surname: Wang
  fullname: Wang, Jiong
  organization: Department of Medicine, Division of Nephrology, University of Rochester Medical Center, Rochester, New York, USA
– sequence: 2
  givenname: Dongmei
  surname: Li
  fullname: Li, Dongmei
  organization: Informatics Core, Clinical, and Translational Science Institute, University of Rochester, Rochester, New York, USA
– sequence: 3
  givenname: Sheldon
  surname: Perry
  fullname: Perry, Sheldon
  organization: Department of Medicine, Division of Nephrology, University of Rochester Medical Center, Rochester, New York, USA
– sequence: 4
  givenname: Shannon P.
  surname: Hilchey
  fullname: Hilchey, Shannon P.
  organization: Department of Medicine, Division of Nephrology, University of Rochester Medical Center, Rochester, New York, USA
– sequence: 5
  givenname: Alexander
  surname: Wiltse
  fullname: Wiltse, Alexander
  organization: Department of Medicine, Division of Nephrology, University of Rochester Medical Center, Rochester, New York, USA
– sequence: 6
  givenname: John J.
  surname: Treanor
  fullname: Treanor, John J.
  organization: Department of Medicine, Division of Infectious Diseases, University of Rochester Medical Center, Rochester, New York, USA
– sequence: 7
  givenname: Mark Y.
  surname: Sangster
  fullname: Sangster, Mark Y.
  organization: Department of Immunology, Vaccine Center, University of Rochester Medical Center, Rochester, New York, USA
– sequence: 8
  givenname: Martin S.
  orcidid: 0000-0002-7095-8682
  surname: Zand
  fullname: Zand, Martin S.
  organization: Department of Medicine, Division of Nephrology, University of Rochester Medical Center, Rochester, New York, USA, Informatics Core, Clinical, and Translational Science Institute, University of Rochester, Rochester, New York, USA, Rochester Center for Health Informatics, University of Rochester Medical Center, Rochester, New York, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34225490$$D View this record in MEDLINE/PubMed
BookMark eNp1kk1vEzEQhi1UREvokSvyEVXa4o_drHNBaipoIlUCUeBqzdqTraONHWynUvgJ_GqcpEUtAl_8Me88Gs87L8mRDx4Jec3ZOedCvVtNXThnrK4nleDPyIngDavahvOjR-djcprSkpUlJVeSvSDHshaiqSfshPyaxgB22NIvCCa7O6Tz_qpc0jr4hInmQGeYMYYh9GGT6Kyhn6NbYTUNIWU694thg_4n0O9gjPOQXfD0IiK9uYU1Wtpt6YXPrkfvTMEOkNF6THvwDuR8T29yBOfTK_J8AUPC0_t9RL59_PD1clZdf7qaX15cV1ArlauFkQBcTTrVKbC16GCMlitR1xJV2y0MihKTrYCxEsw0nRVClh5hZ-3YjCdyROYHrg2w1OtSBMStDuD0_iHEXkPMzgyojbQMmraVqhF1IzmUdCm4KtROWaUK6_2Btd50K7QGffnL8AT6NOLdre7DnVY1G8tS2Ii8vQfE8GODKeuVSwaHATyWfutik5qwpi3ejcjZQQppJfQybKIvbdKc6d0s6N0s6P0saMGL-M3jwv5U9OB8EciDwMSQUsSFNi7v7du5MfwXW_2V9QD-t_43OETSjg
CitedBy_id crossref_primary_10_1093_infdis_jiac022
crossref_primary_10_1093_infdis_jiad276
crossref_primary_10_1080_21645515_2022_2128014
crossref_primary_10_1172_JCI162192
crossref_primary_10_3389_fimmu_2021_696370
crossref_primary_10_3390_pathogens12020169
crossref_primary_10_1038_s41541_024_00874_4
crossref_primary_10_3389_fimmu_2023_1253626
crossref_primary_10_3390_vaccines9121465
crossref_primary_10_1016_j_vaccine_2024_126530
crossref_primary_10_3390_vaccines10060980
Cites_doi 10.1016/j.coviro.2016.12.004
10.1128/JVI.06930-11
10.1056/NEJMp048343
10.1016/j.immuni.2019.06.024
10.1155/2019/3053869
10.1038/nature11414
10.1073/pnas.1111497108
10.1016/j.coi.2018.04.001
10.1038/s41594-018-0025-9
10.1038/srep46426
10.1016/j.vaccine.2009.11.002
10.1093/infdis/jiv210
10.1038/cr.2017.154
10.1038/ni.3684
10.1093/infdis/jix173
10.1093/infdis/jis402
10.1073/pnas.0813390106
10.1371/journal.pone.0049704
10.1016/j.coviro.2013.07.007
10.1126/science.1097211
10.1371/journal.pone.0050830
10.4049/jimmunol.1801149
10.1128/JVI.05397-11
10.1155/2019/9287120
10.1128/JVI.00169-19
10.1056/NEJMc2101667
10.1086/590916
10.1093/infdis/jit180
10.1371/journal.pone.0129858
10.1056/NEJMra0707279
10.1038/s41541-019-0114-8
10.1093/infdis/jiu616
10.1371/journal.pone.0095496
10.1126/science.1256427
10.1016/S0264-410X(00)00395-9
10.1073/pnas.1906613117
10.1126/science.aag1322
10.1128/JVI.00137-12
10.3201/eid1407.071681
10.1073/pnas.1414070111
10.1093/infdis/jiq093
10.1016/j.cell.2015.04.028
10.1371/journal.pone.0193680
10.3390/pathogens8040238
10.1073/pnas.1200039109
10.3888/tmj.17-7
10.1128/JVI.00700-11
ContentType Journal Article
Copyright Copyright © 2021 Wang et al.
Copyright © 2021 Wang et al. 2021 Wang et al.
Copyright_xml – notice: Copyright © 2021 Wang et al.
– notice: Copyright © 2021 Wang et al. 2021 Wang et al.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1128/mBio.00449-21
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic


CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Open Access Full Text
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2150-7511
Editor Rappuoli, Rino
Editor_xml – sequence: 1
  givenname: Rino
  surname: Rappuoli
  fullname: Rappuoli, Rino
ExternalDocumentID oai_doaj_org_article_c3d0a57738524531a6933218c5bb8d88
PMC8406322
mBio00449-21
34225490
10_1128_mBio_00449_21
Genre Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIAID NIH HHS
  grantid: R01 AI129518
– fundername: NIAID NIH HHS
  grantid: R21 AI138500
– fundername: NCATS NIH HHS
  grantid: UL1 TR002001
– fundername: HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  grantid: R21 AI138500
  funderid: https://doi.org/10.13039/100000060
– fundername: Division of Intramural Research, National Institute of Allergy and Infectious Diseases (DIR, NIAID)
  grantid: R01 AI129518
  funderid: https://doi.org/10.13039/100006492
– fundername: HHS | NIH | National Center for Advancing Translational Sciences (NCATS)
  grantid: TR002001
  funderid: https://doi.org/10.13039/100006108
– fundername: ;
  grantid: R01 AI129518
– fundername: ;
  grantid: TR002001
– fundername: ;
  grantid: R21 AI138500
GroupedDBID ---
0R~
53G
5VS
AAFWJ
AAGFI
AAUOK
AAYXX
ADBBV
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
BTFSW
CITATION
DIK
E3Z
EBS
FRP
GROUPED_DOAJ
GX1
H13
HYE
HZ~
KQ8
M48
O5R
O5S
O9-
OK1
P2P
PGMZT
RHI
RNS
RPM
RSF
CGR
CUY
CVF
ECM
EIF
NPM
-
0R
ADACO
BXI
HZ
M~E
RHF
7X8
5PM
ID FETCH-LOGICAL-a488t-fc3aa189b8b8ad42ba6ed182443e87bfce29b8372a6820c5bd223004ebdd6c693
IEDL.DBID DOA
ISSN 2150-7511
IngestDate Wed Aug 27 01:31:33 EDT 2025
Thu Aug 21 18:21:03 EDT 2025
Fri Jul 11 12:06:39 EDT 2025
Tue Dec 28 13:57:58 EST 2021
Thu Apr 03 07:05:47 EDT 2025
Tue Jul 01 01:52:48 EDT 2025
Thu Apr 24 22:56:36 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords HA imprinting
hemagglutinin (HA) antigenic distance
original antigenic sin (OAS)
influenza virus antibody landscape
H5 monovalent influenza vaccine (MIV)
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. https://creativecommons.org/licenses/by/4.0
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a488t-fc3aa189b8b8ad42ba6ed182443e87bfce29b8372a6820c5bd223004ebdd6c693
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Jiong Wang and Dongmei Li contributed equally to this work. Author order for the co-first authors was decided by the primary focus of the paper; being biological, Dr. Wang, who designed and performed the experiments, was listed as first, and Dr. Li, who performed the statistical analysis, was listed second.
Present address: John J. Treanor, Biomedical Advanced Research and Development Authority (BARDA)/HHS/ASPR, Influenza and Emerging Diseases Division 21J14, Washington, DC, USA.
ORCID 0000-0002-7095-8682
OpenAccessLink https://doaj.org/article/c3d0a57738524531a6933218c5bb8d88
PMID 34225490
PQID 2548905703
PQPubID 23479
PageCount 15
ParticipantIDs doaj_primary_oai_doaj_org_article_c3d0a57738524531a6933218c5bb8d88
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8406322
proquest_miscellaneous_2548905703
asm2_journals_10_1128_mBio_00449_21
pubmed_primary_34225490
crossref_citationtrail_10_1128_mBio_00449_21
crossref_primary_10_1128_mBio_00449_21
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-08-31
PublicationDateYYYYMMDD 2021-08-31
PublicationDate_xml – month: 08
  year: 2021
  text: 2021-08-31
  day: 31
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: 1752 N St., N.W., Washington, DC
PublicationTitle mBio
PublicationTitleAbbrev mBio
PublicationTitleAlternate mBio
PublicationYear 2021
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References e_1_3_2_26_2
e_1_3_2_49_2
e_1_3_2_28_2
e_1_3_2_41_2
e_1_3_2_20_2
e_1_3_2_43_2
e_1_3_2_22_2
e_1_3_2_45_2
Francis JT (e_1_3_2_17_2) 1953; 66
e_1_3_2_24_2
e_1_3_2_47_2
Francis JT (e_1_3_2_16_2) 1960; 104
e_1_3_2_9_2
e_1_3_2_37_2
e_1_3_2_7_2
e_1_3_2_18_2
e_1_3_2_39_2
e_1_3_2_10_2
e_1_3_2_31_2
e_1_3_2_52_2
e_1_3_2_5_2
e_1_3_2_12_2
e_1_3_2_33_2
e_1_3_2_3_2
e_1_3_2_14_2
e_1_3_2_35_2
e_1_3_2_50_2
e_1_3_2_27_2
e_1_3_2_48_2
e_1_3_2_29_2
e_1_3_2_40_2
e_1_3_2_21_2
e_1_3_2_42_2
e_1_3_2_23_2
e_1_3_2_44_2
e_1_3_2_25_2
e_1_3_2_46_2
e_1_3_2_15_2
e_1_3_2_38_2
e_1_3_2_8_2
e_1_3_2_6_2
e_1_3_2_19_2
e_1_3_2_30_2
e_1_3_2_53_2
e_1_3_2_32_2
e_1_3_2_51_2
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_4_2
e_1_3_2_13_2
e_1_3_2_36_2
e_1_3_2_2_2
(B22) 2008; 14
Krammer, F, Srivastava, K, Alshammary, H, Amoako, AA, Awawda, MH, Beach, KF, Bermudez-Gonzalez, MC, Bielak, DA, Carreno, JM, Chernet, RL, Eaker, LQ, Ferreri, ED, Floda, DL, Gleason, CR, Hamburger, JZ, Jiang, K, Kleiner, G, Jurczyszak, D, Matthews, JC, Mendez, WA, Nabeel, I, Mulder, LCF, Raskin, AJ, Russo, KT, Salimbangon, AT, Saksena, M, Shin, AS, Singh, G, Sominsky, LA, Stadlbauer, D, Wajnberg, A, Simon, V (B13) 2021; 384
Krause, JC, Tsibane, T, Tumpey, TM, Huffman, CJ, Basler, CF, Crowe, JJE (B47) 2011; 85
Pica, N, Hai, R, Krammer, F, Wang, TT, Maamary, J, Eggink, D, Tan, GS, Krause, JC, Moran, T, Stein, CR, Banach, D, Wrammert, J, Belshe, RB, Garcia-Sastre, A, Palese, P (B31) 2012; 109
Ledgerwood, JE, Zephir, K, Hu, Z, Wei, CJ, Chang, L, Enama, ME, Hendel, CS, Sitar, S, Bailer, RT, Koup, RA, Mascola, JR, Nabel, GJ, Graham, BS (B38) 2013; 208
Khurana, S, Coyle, EM, Dimitrova, M, Castellino, F, Nicholson, K, Del Giudice, G, Golding, H (B42) 2014; 9
Cobey, S, Hensley, SE (B17) 2017; 22
Wang, J, Hilchey, SP, Hyrien, O, Huertas, N, Perry, S, Ramanunninair, M, Bucher, D, Zand, MS (B25) 2015; 10
Abdel-Ghafar, A-N, Chotpitayasunondh, T, Gao, Z, Hayden, FG, Nguyen, DH, de Jong, MD, Naghdaliyev, A, Peiris, JS, Shindo, N, Soeroso, S, Uyeki, TM (B23) 2008; 358
Treanor, JJ, Wilkinson, BE, Masseoud, F, Hu-Primmer, J, Battaglia, R, O'Brien, D, Wolff, M, Rabinovich, G, Blackwelder, W, Katz, JM (B6) 2001; 19
Nachbagauer, R, Palese, P (B14) 2018; 53
Whittle, JR, Zhang, R, Khurana, S, King, LR, Manischewitz, J, Golding, H, Dormitzer, PR, Haynes, BF, Walter, EB, Moody, MA, Kepler, TB, Liao, HX, Harrison, SC (B48) 2011; 108
Gostic, KM, Ambrose, M, Worobey, M, Lloyd-Smith, JO (B2) 2016; 354
Baer, J, Santiago, F, Yang, H, Wu, H, Holden-Wiltse, J, Treanor, J, Topham, DJ (B12) 2010; 28
Wang, J, Hilchey, SP, DeDiego, M, Perry, S, Hyrien, O, Nogales, A, Garigen, J, Amanat, F, Huertas, N, Krammer, F, Martinez-Sobrido, L, Topham, DJ, Treanor, JJ, Sangster, MY, Zand, MS (B33) 2018; 13
Ellebedy, AH, Nachbagauer, R, Jackson, KJL, Dai, YN, Han, J, Alsoussi, WB, Davis, CW, Stadlbauer, D, Rouphael, N, Chromikova, V, McCausland, M, Chang, CY, Cortese, M, Bower, M, Chennareddy, C, Schmitz, AJ, Zarnitsyna, VI, Lai, L, Rajabhathor, A, Kazemian, C, Antia, R, Mulligan, MJ, Ward, AB, Fremont, DH, Boyd, SD, Pulendran, B, Krammer, F, Ahmed, R (B45) 2020; 117
Halliley, JL, Khurana, S, Krammer, F, Fitzgerald, T, Coyle, EM, Chung, KY, Baker, SF, Yang, H, Martinez-Sobrido, L, Treanor, JJ, Subbarao, K, Golding, H, Topham, DJ, Sangster, MY (B40) 2015; 212
Belshe, RB, Frey, SE, Graham, I, Mulligan, MJ, Edupuganti, S, Jackson, LA, Wald, A, Poland, G, Jacobson, R, Keyserling, HL, Spearman, P, Hill, H, Wolff, M (B37) 2011; 203
Andrews, SF, Chambers, MJ, Schramm, CA, Plyler, J, Raab, JE, Kanekiyo, M, Gillespie, RA, Ransier, A, Darko, S, Hu, J, Chen, X, Yassine, HM, Boyington, JC, Crank, MC, Chen, GL, Coates, E, Mascola, JR, Douek, DC, Graham, BS, Ledgerwood, JE, McDermott, AB (B39) 2019; 51
Wang, J, Wiltse, A, Zand, MS (B36) 2019; 8
Francis, JT, Davenport, FM, Hennessy, AV (B16) 1953; 66
Zand, MS, Wang, J, Hilchey, S (B29) 2015; 17
B4
B5
Li, D, Wang, J, Treanor, JJ, Zand, MS (B28) 2019; 2019
Van Hoeven, N, Fox, CB, Granger, B, Evers, T, Joshi, SW, Nana, GI, Evans, SC, Lin, S, Liang, H, Liang, L, Nakajima, R, Felgner, PL, Bowen, RA, Marlenee, N, Hartwig, A, Baldwin, SL, Coler, RN, Tomai, M, Elvecrog, J, Reed, SG, Carter, D (B44) 2017; 7
Ekiert, DC, Kashyap, AK, Steel, J, Rubrum, A, Bhabha, G, Khayat, R, Lee, JH, Dillon, MA, O’Neil, RE, Faynboym, AM, Horowitz, M, Horowitz, L, Ward, AB, Palese, P, Webby, R, Lerner, RA, Bhatt, RR, Wilson, IA (B46) 2012; 489
Levine, MZ, Holiday, C, Jefferson, S, Gross, FL, Liu, F, Li, S, Friel, D, Boutet, P, Innis, BL, Mallett, CP, Tumpey, TM, Stevens, J, Katz, JM (B43) 2019; 4
Subbarao, K (B8) 2018; 28
Krammer, F, Palese, P (B21) 2013; 3
Wu, NC, Wilson, IA (B32) 2018; 25
Nachbagauer, R, Choi, A, Hirsh, A, Margine, I, Iida, S, Barrera, A, Ferres, M, Albrecht, RA, Garcia-Sastre, A, Bouvier, NM, Ito, K, Medina, RA, Palese, P, Krammer, F (B20) 2017; 18
Goji, NA, Nolan, C, Hill, H, Wolff, M, Noah, DL, Williams, TB, Rowe, T, Treanor, JJ (B11) 2008; 198
Hai, R, Krammer, F, Tan, GS, Pica, N, Eggink, D, Maamary, J, Margine, I, Albrecht, RA, Palese, P (B52) 2012; 86
Couch, RB, Decker, WK, Utama, B, Atmar, RL, Nino, D, Feng, JQ, Halpert, MM, Air, GM (B10) 2012; 7
Zhang, A, Stacey, HD, Mullarkey, CE, Miller, MS (B18) 2019; 202
Monto, AS, Malosh, RE, Petrie, JG, Martin, ET (B19) 2017; 215
Ohshima, N, Iba, Y, Kubota-Koketsu, R, Asano, Y, Okuno, Y, Kurosawa, Y (B49) 2011; 85
Galli, G, Medini, D, Borgogni, E, Zedda, L, Bardelli, M, Malzone, C, Nuti, S, Tavarini, S, Sammicheli, C, Hilbert, AK, Brauer, V, Banzhoff, A, Rappuoli, R, Del Giudice, G, Castellino, F (B41) 2009; 106
B51
Francis, JT (B15) 1960; 104
Tesini, BL, Kanagaiah, P, Wang, J, Hahn, M, Halliley, JL, Chaves, FA, Nguyen, PQT, Nogales, A, DeDiego, ML, Anderson, CS, Ellebedy, AH, Strohmeier, S, Krammer, F, Yang, H, Bandyopadhyay, S, Ahmed, R, Treanor, JJ, Martinez-Sobrido, L, Golding, H, Khurana, S, Zand, MS, Topham, DJ, Sangster, MY (B34) 2019; 93
Monto, AS (B3) 2005; 352
Patel, SM, Atmar, RL, El Sahly, HM, Guo, K, Hill, H, Keitel, WA (B7) 2012; 206
Schmidt, AG, Therkelsen, MD, Stewart, S, Kepler, TB, Liao, HX, Moody, MA, Haynes, BF, Harrison, SC (B50) 2015; 161
Ellebedy, AH, Krammer, F, Li, GM, Miller, MS, Chiu, C, Wrammert, J, Chang, CY, Davis, CW, McCausland, M, Elbein, R, Edupuganti, S, Spearman, P, Andrews, SF, Wilson, PC, Garcia-Sastre, A, Mulligan, MJ, Mehta, AK, Palese, P, Ahmed, R (B35) 2014; 111
Nayak, JL, Richards, KA, Yang, H, Treanor, JJ, Sant, AJ (B24) 2015; 211
Zhou, F, Wang, G, Buchy, P, Cai, Z, Chen, H, Chen, Z, Cheng, G, Wan, XF, Deubel, V, Zhou, P (B1) 2012; 86
Fonville, JM, Wilks, SH, James, SL, Fox, A, Ventresca, M, Aban, M, Xue, L, Jones, TC, Le, NM, Pham, QT, Tran, ND, Wong, Y, Mosterin, A, Katzelnick, LC, Labonte, D, Le, TT, van der Net, G, Skepner, E, Russell, CA, Kaplan, TD, Rimmelzwaan, GF, Masurel, N, de Jong, JC, Palache, A, Beyer, WE, Le, QM, Nguyen, TH, Wertheim, HF, Hurt, AC, Osterhaus, AD, Barr, IG, Fouchier, RA, Horby, PW, Smith, DJ (B26) 2014; 346
Couch, RB, Patel, SM, Wade-Bowers, CL, Nino, D (B9) 2012; 7
Li, D, Wang, J, Garigen, J, Treanor, JJ, Zand, MS (B27) 2019; 2019
Smith, DJ, Lapedes, AS, de Jong, JC, Bestebroer, TM, Rimmelzwaan, GF, Osterhaus, AD, Fouchier, RA (B30) 2004; 305
References_xml – ident: e_1_3_2_18_2
  doi: 10.1016/j.coviro.2016.12.004
– ident: e_1_3_2_2_2
  doi: 10.1128/JVI.06930-11
– ident: e_1_3_2_4_2
  doi: 10.1056/NEJMp048343
– ident: e_1_3_2_40_2
  doi: 10.1016/j.immuni.2019.06.024
– ident: e_1_3_2_6_2
– ident: e_1_3_2_29_2
  doi: 10.1155/2019/3053869
– ident: e_1_3_2_47_2
  doi: 10.1038/nature11414
– ident: e_1_3_2_49_2
  doi: 10.1073/pnas.1111497108
– ident: e_1_3_2_5_2
– ident: e_1_3_2_15_2
  doi: 10.1016/j.coi.2018.04.001
– ident: e_1_3_2_33_2
  doi: 10.1038/s41594-018-0025-9
– ident: e_1_3_2_45_2
  doi: 10.1038/srep46426
– ident: e_1_3_2_13_2
  doi: 10.1016/j.vaccine.2009.11.002
– ident: e_1_3_2_41_2
  doi: 10.1093/infdis/jiv210
– ident: e_1_3_2_9_2
  doi: 10.1038/cr.2017.154
– ident: e_1_3_2_21_2
  doi: 10.1038/ni.3684
– ident: e_1_3_2_20_2
  doi: 10.1093/infdis/jix173
– ident: e_1_3_2_8_2
  doi: 10.1093/infdis/jis402
– ident: e_1_3_2_52_2
– ident: e_1_3_2_42_2
  doi: 10.1073/pnas.0813390106
– volume: 104
  start-page: 572
  year: 1960
  ident: e_1_3_2_16_2
  article-title: On the doctrine of original antigenic sin
  publication-title: Proc Am Philos Soc
– ident: e_1_3_2_10_2
  doi: 10.1371/journal.pone.0049704
– ident: e_1_3_2_22_2
  doi: 10.1016/j.coviro.2013.07.007
– ident: e_1_3_2_31_2
  doi: 10.1126/science.1097211
– ident: e_1_3_2_11_2
  doi: 10.1371/journal.pone.0050830
– ident: e_1_3_2_19_2
  doi: 10.4049/jimmunol.1801149
– ident: e_1_3_2_50_2
  doi: 10.1128/JVI.05397-11
– ident: e_1_3_2_28_2
  doi: 10.1155/2019/9287120
– ident: e_1_3_2_35_2
  doi: 10.1128/JVI.00169-19
– ident: e_1_3_2_14_2
  doi: 10.1056/NEJMc2101667
– volume: 66
  start-page: 231
  year: 1953
  ident: e_1_3_2_17_2
  article-title: A serological recapitulation of human infection with different strains of influenza virus
  publication-title: Trans Assoc Am Physicians
– ident: e_1_3_2_12_2
  doi: 10.1086/590916
– ident: e_1_3_2_39_2
  doi: 10.1093/infdis/jit180
– ident: e_1_3_2_26_2
  doi: 10.1371/journal.pone.0129858
– ident: e_1_3_2_24_2
  doi: 10.1056/NEJMra0707279
– ident: e_1_3_2_44_2
  doi: 10.1038/s41541-019-0114-8
– ident: e_1_3_2_25_2
  doi: 10.1093/infdis/jiu616
– ident: e_1_3_2_43_2
  doi: 10.1371/journal.pone.0095496
– ident: e_1_3_2_27_2
  doi: 10.1126/science.1256427
– ident: e_1_3_2_7_2
  doi: 10.1016/S0264-410X(00)00395-9
– ident: e_1_3_2_46_2
  doi: 10.1073/pnas.1906613117
– ident: e_1_3_2_3_2
  doi: 10.1126/science.aag1322
– ident: e_1_3_2_53_2
  doi: 10.1128/JVI.00137-12
– ident: e_1_3_2_23_2
  doi: 10.3201/eid1407.071681
– ident: e_1_3_2_36_2
  doi: 10.1073/pnas.1414070111
– ident: e_1_3_2_38_2
  doi: 10.1093/infdis/jiq093
– ident: e_1_3_2_51_2
  doi: 10.1016/j.cell.2015.04.028
– ident: e_1_3_2_34_2
  doi: 10.1371/journal.pone.0193680
– ident: e_1_3_2_37_2
  doi: 10.3390/pathogens8040238
– ident: e_1_3_2_32_2
  doi: 10.1073/pnas.1200039109
– ident: e_1_3_2_30_2
  doi: 10.3888/tmj.17-7
– ident: e_1_3_2_48_2
  doi: 10.1128/JVI.00700-11
– volume: 2019
  start-page: 9287120
  year: 2019
  ident: B27
  article-title: Continuous readout versus titer-based assays of influenza vaccine trials: sensitivity, specificity, and false discovery rates
  publication-title: Comput Math Methods Med
  doi: 10.1155/2019/9287120
– volume: 161
  start-page: 1026
  year: 2015
  end-page: 1034
  ident: B50
  article-title: Viral receptor-binding site antibodies with diverse germline origins
  publication-title: Cell
  doi: 10.1016/j.cell.2015.04.028
– volume: 4
  start-page: 22
  year: 2019
  ident: B43
  article-title: Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost
  publication-title: NPJ Vaccines
  doi: 10.1038/s41541-019-0114-8
– volume: 203
  start-page: 666
  year: 2011
  end-page: 673
  ident: B37
  article-title: Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiq093
– volume: 18
  start-page: 464
  year: 2017
  end-page: 473
  ident: B20
  article-title: Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins
  publication-title: Nat Immunol
  doi: 10.1038/ni.3684
– ident: B5
  article-title: World Health Organization . 2015 . Influenza at the human-animal interface (summary and assessment as of 6 January 2015) . WHO , Geneva, Switzerland . https://www.who.int/influenza/human_animal_interface/Influenza_Summary_IRA_HA_interface_6January2015.pdf?ua=1 .
– volume: 93
  year: 2019
  ident: B34
  article-title: Broad hemagglutinin-specific memory B cell expansion by seasonal influenza virus infection reflects early-life imprinting and adaptation to the infecting virus
  publication-title: J Virol
  doi: 10.1128/JVI.00169-19
– volume: 358
  start-page: 261
  year: 2008
  end-page: 273
  ident: B23
  article-title: Update on avian influenza A (H5N1) virus infection in humans
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra0707279
– volume: 7
  year: 2012
  ident: B9
  article-title: A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0049704
– ident: B4
  article-title: Centers for Disease Control and Prevention . 2018 . Highly pathogenic Asian avian influenza A(H5N1) virus . Centers for Disease Control and Prevention , Atlanta, GA . https://www.cdc.gov/flu/avianflu/h5n1-virus.htm .
– volume: 10
  year: 2015
  ident: B25
  article-title: Multi-dimensional measurement of antibody-mediated heterosubtypic immunity to influenza
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0129858
– volume: 208
  start-page: 418
  year: 2013
  end-page: 422
  ident: B38
  article-title: Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jit180
– volume: 22
  start-page: 105
  year: 2017
  end-page: 111
  ident: B17
  article-title: Immune history and influenza virus susceptibility
  publication-title: Curr Opin Virol
  doi: 10.1016/j.coviro.2016.12.004
– volume: 109
  start-page: 2573
  year: 2012
  end-page: 2578
  ident: B31
  article-title: Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1200039109
– volume: 215
  start-page: 1782
  year: 2017
  end-page: 1788
  ident: B19
  article-title: The doctrine of original antigenic sin: separating good from evil
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jix173
– volume: 13
  year: 2018
  ident: B33
  article-title: Broad cross-reactive IgG responses elicited by adjuvanted vaccination with recombinant influenza hemagglutinin (rHA) in ferrets and mice
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0193680
– volume: 17
  start-page: 17-7
  year: 2015
  ident: B29
  article-title: Graphical representation of proximity measures for multidimensional data: classical and metric multidimensional scaling
  publication-title: Math J
  doi: 10.3888/tmj.17-7
– volume: 25
  start-page: 115
  year: 2018
  end-page: 121
  ident: B32
  article-title: Structural insights into the design of novel anti-influenza therapies
  publication-title: Nat Struct Mol Biol
  doi: 10.1038/s41594-018-0025-9
– volume: 9
  year: 2014
  ident: B42
  article-title: Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0095496
– volume: 28
  start-page: 1
  year: 2018
  end-page: 2
  ident: B8
  article-title: Avian influenza H7N9 viruses: a rare second warning
  publication-title: Cell Res
  doi: 10.1038/cr.2017.154
– volume: 66
  start-page: 231
  year: 1953
  end-page: 239
  ident: B16
  article-title: A serological recapitulation of human infection with different strains of influenza virus
  publication-title: Trans Assoc Am Physicians
– volume: 86
  start-page: 5774
  year: 2012
  end-page: 5781
  ident: B52
  article-title: Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes
  publication-title: J Virol
  doi: 10.1128/JVI.00137-12
– volume: 3
  start-page: 521
  year: 2013
  end-page: 530
  ident: B21
  article-title: Influenza virus hemagglutinin stalk-based antibodies and vaccines
  publication-title: Curr Opin Virol
  doi: 10.1016/j.coviro.2013.07.007
– ident: B51
  article-title: Code of Federal Regulations . 2002 . Title 45. Public welfare. Subtitle A. Department of Health and Human Services. Subchapter C. Administrative data standards and related requirements. Part 164. Security and privacy. Subpart E. Privacy of individually identifiable health information. 45 CFR 164.514 . https://www.govinfo.gov/content/pkg/CFR-2002-title45-vol1/pdf/CFR-2002-title45-vol1-sec164-514.pdf .
– volume: 53
  start-page: 51
  year: 2018
  end-page: 57
  ident: B14
  article-title: Development of next generation hemagglutinin-based broadly protective influenza virus vaccines
  publication-title: Curr Opin Immunol
  doi: 10.1016/j.coi.2018.04.001
– volume: 85
  start-page: 10905
  year: 2011
  end-page: 10908
  ident: B47
  article-title: A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin
  publication-title: J Virol
  doi: 10.1128/JVI.00700-11
– volume: 8
  start-page: 238
  year: 2019
  ident: B36
  article-title: A complex dance: measuring the multidimensional worlds of influenza virus evolution and anti-influenza immune responses
  publication-title: Pathogens
  doi: 10.3390/pathogens8040238
– volume: 2019
  start-page: 3053869
  year: 2019
  ident: B28
  article-title: Improved specificity and false discovery rates for multiplex analysis of changes in strain-specific anti-influenza IgG
  publication-title: Comput Math Methods Med
  doi: 10.1155/2019/3053869
– volume: 14
  year: 2008
  ident: B22
  article-title: Toward a unified nomenclature system for highly pathogenic avian influenza virus (H5N1)
  publication-title: Emerg Infectious Diseases
  doi: 10.3201/eid1407.071681
– volume: 346
  start-page: 996
  year: 2014
  end-page: 1000
  ident: B26
  article-title: Antibody landscapes after influenza virus infection or vaccination
  publication-title: Science
  doi: 10.1126/science.1256427
– volume: 305
  start-page: 371
  year: 2004
  end-page: 376
  ident: B30
  article-title: Mapping the antigenic and genetic evolution of influenza virus
  publication-title: Science
  doi: 10.1126/science.1097211
– volume: 85
  start-page: 11048
  year: 2011
  end-page: 11057
  ident: B49
  article-title: Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5
  publication-title: J Virol
  doi: 10.1128/JVI.05397-11
– volume: 212
  start-page: 1270
  year: 2015
  end-page: 1278
  ident: B40
  article-title: High-affinity H7 head and stalk domain-specific antibody responses to an inactivated influenza H7N7 vaccine after priming with live attenuated influenza vaccine
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiv210
– volume: 211
  start-page: 1408
  year: 2015
  end-page: 1417
  ident: B24
  article-title: Effect of influenza A(H5N1) vaccine prepandemic priming on CD4+ T-cell responses
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiu616
– volume: 108
  start-page: 14216
  year: 2011
  end-page: 14221
  ident: B48
  article-title: Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1111497108
– volume: 206
  start-page: 1069
  year: 2012
  end-page: 1077
  ident: B7
  article-title: Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jis402
– volume: 7
  year: 2012
  ident: B10
  article-title: Evaluations for in vitro correlates of immunogenicity of inactivated influenza A H5, H7 and H9 vaccines in humans
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0050830
– volume: 354
  start-page: 722
  year: 2016
  end-page: 726
  ident: B2
  article-title: Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting
  publication-title: Science
  doi: 10.1126/science.aag1322
– volume: 198
  start-page: 635
  year: 2008
  end-page: 641
  ident: B11
  article-title: Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant
  publication-title: J Infect Dis
  doi: 10.1086/590916
– volume: 104
  start-page: 572
  year: 1960
  end-page: 578
  ident: B15
  article-title: On the doctrine of original antigenic sin
  publication-title: Proc Am Philos Soc
– volume: 51
  start-page: 398
  year: 2019
  end-page: 410.e5
  ident: B39
  article-title: Activation dynamics and immunoglobulin evolution of pre-existing and newly generated human memory B cell responses to influenza hemagglutinin
  publication-title: Immunity
  doi: 10.1016/j.immuni.2019.06.024
– volume: 489
  start-page: 526
  year: 2012
  end-page: 532
  ident: B46
  article-title: Cross-neutralization of influenza A viruses mediated by a single antibody loop
  publication-title: Nature
  doi: 10.1038/nature11414
– volume: 117
  start-page: 17957
  year: 2020
  end-page: 17964
  ident: B45
  article-title: Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1906613117
– volume: 86
  start-page: 6970
  year: 2012
  end-page: 6978
  ident: B1
  article-title: A triclade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenza H5N1 viruses
  publication-title: J Virol
  doi: 10.1128/JVI.06930-11
– volume: 19
  start-page: 1732
  year: 2001
  end-page: 1737
  ident: B6
  article-title: Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(00)00395-9
– volume: 384
  start-page: 1372
  year: 2021
  end-page: 1374
  ident: B13
  article-title: Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine
  publication-title: N Engl J Med
  doi: 10.1056/NEJMc2101667
– volume: 7
  start-page: 46426
  year: 2017
  ident: B44
  article-title: A formulated TLR7/8 agonist is a flexible, highly potent and effective adjuvant for pandemic influenza vaccines
  publication-title: Sci Rep
  doi: 10.1038/srep46426
– volume: 202
  start-page: 335
  year: 2019
  end-page: 340
  ident: B18
  article-title: Original antigenic sin: how first exposure shapes lifelong anti-influenza virus immune responses
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1801149
– volume: 106
  start-page: 3877
  year: 2009
  end-page: 3882
  ident: B41
  article-title: Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0813390106
– volume: 111
  start-page: 13133
  year: 2014
  end-page: 13138
  ident: B35
  article-title: Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1414070111
– volume: 352
  start-page: 323
  year: 2005
  end-page: 325
  ident: B3
  article-title: The threat of an avian influenza pandemic
  publication-title: N Engl J Med
  doi: 10.1056/NEJMp048343
– volume: 28
  start-page: 907
  year: 2010
  end-page: 915
  ident: B12
  article-title: B cell responses to H5 influenza HA in human subjects vaccinated with a drifted variant
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2009.11.002
SSID ssj0000331830
Score 2.3625112
Snippet The antigenic shift and draft of hemagglutinin (HA) in influenza viruses is accepted as one of the major reasons for immune evasion. The analysis of B cell...
Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual's H5...
Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual’s H5...
ABSTRACT Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual’s...
SourceID doaj
pubmedcentral
proquest
asm2
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage e0044921
SubjectTerms Adult
Antibodies, Viral - blood
Antibodies, Viral - immunology
Antigenic Drift and Shift
Cohort Studies
H5 monovalent influenza vaccine (MIV)
HA imprinting
hemagglutinin (HA) antigenic distance
Hemagglutinin Glycoproteins, Influenza Virus - immunology
Humans
Immunoglobulin G - blood
Immunoglobulin G - immunology
Influenza A Virus, H5N1 Subtype - genetics
Influenza A Virus, H5N1 Subtype - immunology
Influenza Vaccines - administration & dosage
Influenza Vaccines - immunology
influenza virus antibody landscape
Influenza, Human - prevention & control
Middle Aged
original antigenic sin (OAS)
Research Article
Vaccination - methods
Vaccines
SummonAdditionalLinks – databaseName: American Society for Microbiology Open Access
  dbid: AAUOK
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELaqVkhcEJRXClRGIE64ZB0ncY67VcsWBFSURb1ZfqVdqU2qJj0sP4FfzYzzEFtRiWPiiRN7Hpmxx98Q8tblZcl5XDKde8eEs5pJU06YgYYcWF64As8Of_mazRfi02l6ukH4cBamn8FmTzeXYSN_1GwuP1zOlvUebkEWDM-Ob6Xg7oNUb02ni2-fx5WVOEE5jQdAzdvPge2FvvnafyjA9f_Lx7ydKvnXv-fwIXnQO4102nH5Ednw1Ta515WRXD0mvyGW1u5iRb97HcwXPTr7CBch-9U3tK3pHLNekBwCfTpP6TGi-rNZXTctPerqlPzS9Ke2dtktD8LLPD0511feUbOi06pF2M6lpSF7zju0kNjxcSgLdkZPQq2J5glZHB782J-zvsYC06C6LSttovVEFkYaqZ3gRmfeQcwhROJlbkrrObQlOdcZ-Ao2NQ78CZhKb5zLbFYkT8lmVVf-OaEpF6VwmY954RD2zDiTg7-RlWlsNfjwEXmDE68GFqsQf3CpkD0qsEfxSUTeD3xRtocpxxFc3EX-biS_6vA57iKcIZNHIoTVDjdAyFSvpcomLtZpjgg_XIB10jDABJwgGLeRTsqIvB5ERIEa4t6KrjxwTkGcLYsY4cwi8qwTmfFVieAYhscRydeEae1b1luq5XmA-obwOwOTu_NfU_eC3OeYcRNWvF-Szfb6xr8Cl6k1u72O_AHMxBR5
  priority: 102
  providerName: American Society for Microbiology
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bb9MwFLbQEBIviDsZA3kC8YRH6jiJ84CmFTE6pKGJUbQ3y7d0lbpka4JE-Qn86p3jpGWdtjceW582sc_F30mOv0PIW5eXJedxyXTuHRPOaiZNOWAGBnJQeeEKPDt8-C0bjcXXk_TkH6VQv4DNjakd9pMaz2c7vy8Wu-DwH7sDMPLD2XBa7-CbyYLhkfK7sClxNPDDHumHoJyg8cZLls3rv4KArJszvrY5BQ7_m4Dn9frJKxvS_kPyoEeSdK9T_SNyx1ePyb2ut-TiCfkLCbZ2swX97nWIafRg8gU-hJJY39C2piMshUFxyP7pKKVHSPXPhnXdtPSga17yR9Of2tpp98wQLubp8ak-946aBd2rWuTynFoaSuq8w7CJf3wUeoVN6HFoQNE8JeP9zz8-jVjfeIFp8OeWlTbReiALI43UTnCjM-8gEREi8TI3pfUcxpKc6wwAhE2NA5ABS-mNc5nNiuQZ2ajqyr8gNOWiFC7zMS8ccqEZZ3IAIVmZxlYDsI_IG1x4tVS8CkkJlwrVo4J6FB9E5P1SL8r23OU4g9lt4u9W4ucdacdtgkNU8koIubbDF_V8onrXVTZxsU5zpP3hAkKWhgkmgIxg3kY6KSOyvTQRBb6JL1x05UFzCpJvWcTIcRaR553JrC6VCI65eRyRfM2Y1u5lfaSangb-b8jJM4jDm__j5l-S-xyrdMJT8i2y0c5_-VcAs1rzOjjQJbrsJ0Y
  priority: 102
  providerName: Scholars Portal
Title Broadly Reactive IgG Responses to Heterologous H5 Prime-Boost Influenza Vaccination Are Shaped by Antigenic Relatedness to Priming Strains
URI https://www.ncbi.nlm.nih.gov/pubmed/34225490
https://journals.asm.org/doi/10.1128/mBio.00449-21
https://www.proquest.com/docview/2548905703
https://pubmed.ncbi.nlm.nih.gov/PMC8406322
https://doaj.org/article/c3d0a57738524531a6933218c5bb8d88
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVABX
  databaseName: American Society for Microbiology Open Access
  customDbUrl:
  eissn: 2150-7511
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000331830
  issn: 2150-7511
  databaseCode: AAUOK
  dateStart: 20100518
  isFulltext: true
  titleUrlDefault: https://journals.asm.org/
  providerName: American Society for Microbiology
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 2150-7511
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000331830
  issn: 2150-7511
  databaseCode: KQ8
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Open Access Full Text
  customDbUrl:
  eissn: 2150-7511
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000331830
  issn: 2150-7511
  databaseCode: DOA
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2150-7511
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000331830
  issn: 2150-7511
  databaseCode: DIK
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 2150-7511
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000331830
  issn: 2150-7511
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 2150-7511
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000331830
  issn: 2150-7511
  databaseCode: GX1
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2150-7511
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000331830
  issn: 2150-7511
  databaseCode: RPM
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 2150-7511
  dateEnd: 20250831
  omitProxy: true
  ssIdentifier: ssj0000331830
  issn: 2150-7511
  databaseCode: M48
  dateStart: 20100501
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQVkhcEJRXClRGIE6YZh0ncY67qO0WVKgoi_Zm-ZV2pTapmvSw_Qn8amac7GoXUXHhEinxKHE8Y3s-e_wNIe9cXpacxyXTuXdMOKuZNOWQGSjIQeWFK_Ds8PHXbDIVn2fpbC3VF8aEdfTAXcPt2cTFOs2RdIULMBidAQSHecmmxkgnwzFfmMbWwFQYgxO01XhJqsnl3uV4Xn_E7cuCIS_oQDeXfGMuCpT9f_Mz_wyXXJt_Dh6Rh73jSEddhR-Te77aJve7VJKLJ-QX4GntLhb0u9dhCKNHZ4dwEyJgfUPbmk4w8gXFAezTSUpPkNmfjeu6aelRl6vkVtOf2tp5t0QIH_P09FxfeUfNgo6qFqk755aGCDrvcJTEF5-E1GBn9DTkm2iekunB_o9PE9bnWWAaum_LSptoPZSFkUZqJ7jRmXeAO4RIvMxNaT2HsiTnOgN_ARregU8BTemNc5kFfTwjg6qu_AtCQUelcJmPeeGQ-sw4k4PPkZVpbDX48RF5iw2v-o7SqIBBuFSoHhXUo_gwIh-WelG2pyrHP7i4S_z9Svyq4-i4S3CMSl4JIbV2eAAGp3qDU_8yuIi8WZqIgq6I-yu68qA5BVhbFjFSmkXkeWcyq08lgiMUjyOSbxjTRl02S6r5eaD7BgiewbC78z8q_5I84BiUExbFX5FBe33jX4NX1ZpdsjUaTb992Q0dCa6HsyFcj4X8DT4iItA
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Zb9QwEB5VWyF4QdyE0wjEEylZ53IedxFllx5UtIv6ZvlKu2ibVCQ8LD-BX82Mk12xFZV4TDyJY8-RGXv8DcAbm5cl51EZqtzZMLFGhUKXw1BjQ44sL2xBZ4cPDrPJLPl8mp5uQbY6C_Od6vIumh3VXPh9fFJsWoju6xGK9xfjeb1D25BFSOfHt1NeRHwA26PR7MveenUliklWoxWo5tXn0P5iB3zjX-Qh-__lZ15Nl_zr_7N7B273jiMbdZy-C1uuugc3ulKSy_vwG-NpZRdL9tUpb8LY9OwTXvgMWNewtmYTynwhcgz22SRlR4TsH47rumnZtKtV8kuxb8qYebdEiJ05dnyuLp1leslGVUvQnXPDfAads2Ql6cVHvjTYGTv29SaaBzDb_XjyYRL2dRZCherbhqWJlRqKQgstlE24VpmzGHckSexErkvjOLbFOVcZ-gsm1RZ9CpxKp63NTFbED2FQ1ZV7DCzlSZnYzEW8sAR9pq3O0efIyjQyCv34AF7TxMteURrpYxAuJLFHevZIPgzg3Yov0vRQ5TSCxXXkb9fklx1Gx3WEY2Lymoigtf0NlDTZa6o0sY1UmhPKD0_QQikcYIyOEI5bCytEAK9WIiJRFWl_RVUOOScx1hZFRJBmATzqRGbdVZxwCsWjAPINYdr4ls2Wan7u4b4xBM_Q7D75r6l7CTcnJwf7cn96uPcUbnHKwPEr4M9g0P746Z6jC9XqF72-_AHzzxjK
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELemTSBeEN8E2DAC8US21HES57FllJbBqBhFe7P8la3SllQkPJQ_gb96d05S0YlJPCa-OLHvI3f2-XeEvLFZUTAWFaHKnA25NSoUuhiEGhoyYHluczw7_OU4ncz5p9PkdIuk_VmYbgbrfVVf-o181OylLbp6hOLgcrSo9nEbMg_x_PhOwoQAad4ZDudfj9arK1GMshr1oJrXnwP7C_2zjX-Rh-z_l595PV3yr__P-B652zmOdNhy-j7ZcuUDcqstJbl6SP5APK3sxYp-c8qbMDo9-wgXPgPW1bSp6AQzX5Acgn06SegMkf3DUVXVDZ22tUp-K_pDGbNolwjhZY6enKuls1Sv6LBsELpzYajPoHMWrSR2PPOlwc7oia83UT8i8_GH7-8nYVdnIVSgvk1YmFipgci10EJZzrRKnYW4g_PYiUwXxjFoizOmUvAXTKIt-BQwlU5bm5o0jx-T7bIq3VNCE8YLblMXsdwi9Jm2OgOfIy2SyCjw4wPyGide9myWPgZhQiJ7pGePZIOAvOv5Ik0HVY4juLiJ_O2afNlidNxEOEImr4kQWtvfAEGTnaZKE9tIJRmi_DAOFkrBAGNwhGDcWlghAvKqFxEJqoj7K6p0wDkJsbbII4Q0C8iTVmTWr4o5w1A8Cki2IUwb37LZUi7OPdw3hOApmN1n_zV1L8nt2eFYfp4eHz0ndxgm4PgF8Bdku_n5y-2CB9XovU5drgD23hh4
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Broadly+Reactive+IgG+Responses+to+Heterologous+H5+Prime-Boost+Influenza+Vaccination+Are+Shaped+by+Antigenic+Relatedness+to+Priming+Strains&rft.jtitle=mBio&rft.au=Jiong+Wang&rft.au=Dongmei+Li&rft.au=Sheldon+Perry&rft.au=Shannon+P.+Hilchey&rft.date=2021-08-31&rft.pub=American+Society+for+Microbiology&rft.eissn=2150-7511&rft.volume=12&rft.issue=4&rft_id=info:doi/10.1128%2FmBio.00449-21&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_c3d0a57738524531a6933218c5bb8d88
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2150-7511&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2150-7511&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2150-7511&client=summon